Check out your Company Bowl for anonymous work chats.
We’re pleased to announce the appointment of experienced business and public sector leader Hunada Nouss OBE to CPI’s Board of Directors as a Non-Executive Director. Hunada brings significant leadership experience across business and the public sector, further strengthening CPI’s strategic and governance expertise as we support innovation and growth across the UK. Her appointment reflects CPI’s continued focus on strong board leadership to help guide the organisation as it works with partners to accelerate innovation and deliver impact.
A new £5 million, UK-led programme has been launched to accelerate the development and adoption of next-generation cancer diagnostics, bringing industry, clinicians, patients and technology leaders together to overcome long-standing barriers to early detection. The Next Generation Cancer Diagnostics programme (NG-Dx), led by CPI and funded by the UK government’s Office for Life Sciences, will run for 18 months from January 2026. Designed as a pre-competitive programme, NG-Dx combines technical delivery with structured industry and public engagement to ensure innovation translates into clinically relevant, trusted and investable solutions.
From chemistry to component: New NCC and CPI partnership to strengthen UK materials capability.
CPI has appointed Greig Rooney as Managing Director for Pharma and HealthTech. He joins CPI’s Executive Leadership Team to accelerate innovation that transforms patient outcomes and advances UK health resilience.
Revolutionary RNA vaccines technology could bring humanity one step closer to global vaccine equity. RNAssist and CPI have collaborated to develop TheraPHIX™, a new way of storing RNA vaccines without needing a freezer. It could help deliver potentially life-saving vaccines to hard-to-reach regions, improving global health equity.
CPI and tech giants Siemens have signed a new Memorandum of Understanding (MoU), committing to enhance collaborative research into advanced manufacturing processes. The enhanced partnership will allow CPI to leverage Siemens’ expertise and technology across the full range of its research portfolio, ranging from battery materials innovation and photonics to printed electronics. The new agreement will follow on from an initial collaboration agreement that was signed in 2020, under which Siemens has provided advanced hardware and software to underpin the development of our Medicines Manufacturing Innovation Centre in Renfrewshire, Scotland.
A collaboration between CPI, academia, and industry leaders within pharma and digital will develop a working model that could help medicines reach patients up to a year faster. The model is a cloud-first manufacturing facility that will use technologies such as artificial intelligence (AI), machine learning and the Internet of Things (IoT) to accelerate the speed at which new medicines are made. Using these technologies in pharma could lead to patients gaining faster access to innovative treatments and could reduce operational costs for manufacturers by up to 30%.
CPI is one of a number of partners involved in creating The Centre of Expertise in Advanced Materials and Sustainability (CEAMS) and bringing it to Rochdale. The Centre will support the development and commercialisation of advanced sustainable materials and anchor high-value investment in the Greater Manchester region.
CPI is set to create a new centre of excellence for manufacturing cutting-edge medicines after a multi-million-pound fund was announced in the Autumn Statement on the 22nd Nov 2023. The Oligonucleotide Manufacturing Innovation Centre of Excellence will focus on developing innovative and sustainable manufacturing techniques in an emerging area of medicine known as oligonucleotides.
CPI opens RNA Centre of Excellence Opened in Darlington, this first-of-its-kind facility will drive UK leadership in pandemic preparation and RNA therapeutic innovation. The £26.4 million RNA Centre of Excellence will form a UK hub with the capability to develop and manufacture treatments for incurable or hard-to-treat illnesses.
